ISSN |
1007-9327 (print) and 2219-2840 (online) |
Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
Copyright |
© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved. |
Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
Website |
http://www.wjgnet.com |
Category |
Gastroenterology & Hepatology |
Manuscript Type |
Review |
Article Title |
Biological therapy in inflammatory bowel diseases: Access in Central and Eastern Europe
|
Manuscript Source |
Invited Manuscript |
All Author List |
Fanni Rencz, Márta Péntek, Martin Bortlik, Edyta Zagorowicz, Tibor Hlavaty, Andrzej Śliwczyński, Mihai M Diculescu, Limas Kupcinskas, Krisztina B Gecse, László Gulácsi and Peter L Lakatos |
Funding Agency and Grant Number |
|
Corresponding Author |
Péter L Lakatos, MD, DSc, PhD, 1st Department of Medicine, Semmelweis University, Korányi S. 2/A, H-1083 Budapest, Hungary. lakatos.peter_laszlo@med.semmelweis-univ.hu |
Key Words |
Inflammatory bowel diseases; Ulcerative colitis; Biological therapy; Access; Europe; Central and Eastern; Crohn’s disease |
Core Tip |
Great heterogeneity ranging up to 96-fold difference in access of inflammatory bowel diseases (IBD) patients to biologicals can be found across Central and Eastern Europe (CEE): Poland, Bulgaria, Romania, and the Baltic States have, to date, fallen behind Hungary, Slovakia and the Czech Republic. The following factors did not explain the considerable variations among the CEE countries: differences in prevalence and incidence, price of biologicals, total expenditure on health, geographical access, clinical guidelines, and cost-effectiveness results. We assume that health deterioration linked to IBD might be valued differently against other systemic inflammatory conditions in distinct countries which contributes to the great heterogeneity. |
Publish Date |
2015-02-11 17:56 |
Citation |
Rencz F, Péntek M, Bortlik M, Zagorowicz E, Hlavaty T, Śliwczyński A, Diculescu MM, Kupcinskas L, Gecse KB, Gulácsi L, Lakatos PL. Biological therapy in inflammatory bowel diseases: access in Central and Eastern Europe. World J Gastroenterol 2015; 21(6): 1728-1737 |
URL |
http://www.wjgnet.com/1007-9327/full/v21/i6/1728.htm |
DOI |
http://dx.doi.org/10.3748/wjg.v21.i6.1728 |